drugset
drugset / Trial / NCT02595242

Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma

NCT02595242 ↗

Phase 1 Withdrawn CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Mitoxantrone Hydrochloride Liposome Injection plus Cyclophosphamide,Vincristine and Prednison(CNOP)is safe and effective in the treatment of Diffuse Large B Cell Lymphoma.

Timeline

Start
2015-06
Primary completion
2016-12
Completion
2017-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoxantrone Small molecule 12 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 16 mg/m2 Intravenous
Subject Mitoxantrone Small molecule 20 mg/m2 Intravenous
Background Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Background Prednisone Other / unclassified 100 mg Oral
Background Vincristine Small molecule 0.3 mg/ml Intravenous
Background Vincristine Small molecule 0.5 mg/ml Intravenous

Indications

diffuse large B-cell lymphoma